Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007117 · ClinicalTrials.gov registry record · Phase 1
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
A Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07007117: Recruiting Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma, sponsored by Stephan Grupp MD PhD.
NCT07007117 is a Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 38 participants, below the 61-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07007117, a Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Primary Outcome
The Maximum Tolerated Dose of PHOX2B-PC CAR T cells will be determined by measuring the incidence of dose limiting toxicities following administration of the product.
Conditions Studied
Interventions
- BIOLOGICAL PHOX2B PC-CAR T Cells
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2035-06-30 |
| Phase | Phase 1 |
What NCT07007117 shows while recruiting
NCT07007117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 61-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (38% lower).
The record links to 3 conditions, with High-risk Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which PHOX2B PC-CAR T Cells is the first listed.
NCT07007117 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07007117 about?
NCT07007117 is a clinical study titled "PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma". This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
What is the current status of trial NCT07007117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-06-20. Estimated completion is 2035-06-30.
What conditions does trial NCT07007117 study?
This clinical trial studies the following conditions: High-risk Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma.
What interventions are being tested in trial NCT07007117?
The interventions under investigation include: PHOX2B PC-CAR T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07007117?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007117 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07007117's enrollment target sits among peer trials
38 10th of 9 the lowest of 9 other High-risk Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High-risk Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
RECRUITING
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI